Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 467 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... February 18, 2021 FDA Approves Injectable Nivolumab, an Alternative to IV Infusion February 19, 2025 5 Tips to Move Beyond the Bedside May 17, 2021 Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... March 23, 2022 Load more HOT NEWS Patients with Early Stage NSCLC Have a Higher TMB in Comparison... Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival...
